Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Global Healthy Living Foundation Says Hims & Hers Health Super Bowl ad omits safety risks and side effects of its weight loss ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Independence Blue Cross, a major insurance company, is no longer covering drugs like Zepbound ... letter she received from the insurance company said, "Starting January 1st, 2025, weight loss ...

A tight supply of Novo's semaglutide and Lilly's tirzepatide - sold as Wegovy and Zepbound, respectively, for weight loss - has fueled demand for compounded versions. Median first-month prices ...

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to ...

CEO Letter to Stakeholders Dear Fellow Stakeholders ... In addition, the top two performing weight loss arms in the study - DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation ...

Hims and Hers is airing an ad about its copycat GLP-1 drugs during Sunday’s Super Bowl. Critics say it violates FDA rules.